Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 18 results
Filters: First Letter Of Title is N  [Clear All Filters]
Found 18 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

N

Mitsuya Y, Winters MA, W Fessel J, et al. "N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure." AIDS Res. Hum. Retroviruses. 2006;22(12):1300-5.
Robertson KR, Miyahara S, Lee A, et al. "Neurocognition in maraviroc- compared to tenofovir: a double blind randomized placebo controlled trial ACTG A5303." AIDS. 2016.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
Parsons TD, Tucker KA, Hall CD, et al. "Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection." AIDS. 2006;20(12):1591-5.
Cespedes MS, Aberg JA. "Neuropsychiatric complications of antiretroviral therapy." Drug Saf. 2006;29(10):865-74.
Dong BJ, Zheng Y, Hughes MD, et al. "Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women." AIDS. 2012;26(7):833-41.
Lockman S, Hughes M, Sawe F, et al. "Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial." PLoS Med.. 2012;9(6):e1001236.
Lederman MM, Miller V, Weller I, Deeks SG. "A new approach for 'deep salvage' trials in advanced HIV infection." AIDS. 2007;21(12):1503-6.
McLaughlin BE, Baumgarth N, Bigos M, et al. "Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms." Cytometry A. 2008;73(5):411-20.
McLaughlin BE, Baumgarth N, Bigos M, et al. "Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach." Cytometry A. 2008;73(5):400-10.
Gandhi RT, Coombs RW, Chan ES, et al. "No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;59(3):229-35.
Gandhi RT, Bosch RJ, Aga E, et al. "No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy." J. Infect. Dis.. 2010;201(2):293-6.
Ribaudo HJ, Benson CA, Zheng Y, et al. "No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT." Clin. Infect. Dis.. 2011;52(7):929-40.
Haubrich RH, Jiang H, Swanstrom R, et al. "Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359." HIV Clin Trials. 2007;8(2):63-7.
X Hu J, Lagakos SW. "Nonparametric estimation of the mean function of a stochastic process with missing observations." Lifetime Data Anal. 2007;13(1):51-73.
May S, Degruttola V. "Nonparametric tests for two-group comparisons of dependent observations obtained at varying time points." Biometrics. 2007;63(1):194-200.
Jordan PS, Poon A, Eron J, et al. "A novel codon insert in protease of clade B HIV type 1." AIDS Res. Hum. Retroviruses. 2009;25(5):547-50.
Dooley KE, Savic RM, Park J-G, et al. "Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers." Antimicrob. Agents Chemother.. 2015;59(6):3399-405.